|
1
|
Fagerhol MK, Dale I and Andersson T: A
radioimmunoassay for a granulocyte protein as a marker in studies
on the turnover of such cells. Bull Eur Physiopathol Respir.
16:273–282. 1980.PubMed/NCBI
|
|
2
|
Steinbakk M, Naess-Andresen CF, Lingaas E,
Dale I, Brandtzaeg P and Fagerhol MK: Antimicrobial actions of
calcium binding leucocyte L1 protein, calprotectin. Lancet.
336:763–765. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sohnle PG, Collins-Lech C and Wiessner JH:
Antimicrobial activity of an abundant calcium-binding protein in
the cytoplasm of human neutrophils. J Infect Dis. 163:187–192.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Røseth AG, Schmidt PN and Fagerhol MK:
Correlation between faecal excretion of indium-111-labelled
granulocytes and calprotectin, a granulocyte marker protein, in
patients with inflammatory bowel disease. Scand J Gastroenterol.
34:50–54. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fagerhol MK, Andersson KB, Andresen CF
Naess, Brandtzaeg P and Dale I: Calprotectin (the L1 leucoyte
protein)Stimulus Response Coupling: The Role of Intracellular
Calcium Binding Proteins. Smith VL and Dedman JR: CRC Press Inc.;
Boca Raton, FL: pp. 187–210. 1990
|
|
6
|
Gaya DR and Mackenzie JF: Faecal
calprotectin: A bright future for assessing diseaseactivity in
Crohn's disease. QJM. 95:557–558. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yiu S, Mikami M and Yamazaki M: Induction
of apoptoic cell death in mouse lymphoma and human leukaemia cell
lines by a calcium-binding protein complex, calprotectin, derived
from inflammatory peritoneal exudate cells. J Leukoc Biol.
336:763–765. 1995.
|
|
8
|
Johne B, Fagerhol MK, Lyberg T, Prydz H,
Brandtzaeg P, Naess-Andresen CF and Dale I: Functional and clinical
aspects of the myelomonocyte protein calprotectin. Mol Pathol.
50:113–123. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Røseth AG, Fagerhol MK, Aadland E and
Schjønsby H: Assessment of the neutrophil dominating protein
calprotectin in feces. A methodologic study. Scand J Gastroenterol.
27:793–798. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lasson A, Kilander A and Stotzer PO:
Diagnostic yield of colonoscopy based on symptoms. Scand J
Gastroenterol. 43:356–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bunn SK, Bisset WM, Main MJ and Golden BE:
Fecal calprotectin as a measure of disease activity in childhood
inflammatory bowel disease. J Pediatr Gastroenterol Nutr.
32:171–177. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Røseth AG, Kristinsson J, Fagerhol MK,
Schjønsby H, Aadland E, Nygaard K and Roald B: Faecal calprotectin:
A novel test for the diagnosis of colorectal cancer? Scand J
Gastroenterol. 28:1073–1076. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meling TR, Aabakken L, Røseth A and Osnes
M: Faecal calprotectin shedding after short-term treatment with
non-steroidal anti-inflammatory drugs. Scand J Gastroenterol.
31:339–344. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tibble JA, Sigthorsson G, Foster R, Scott
D, Fagerhol MK, Roseth A and Bjarnason I: High prevalence of NSAID
enteropathy as shown by a simple faecal test. Gut. 45:362–366.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaser A, Zeissig S and Blumberg RS:
Inflammatory bowel disease. Annu Rev Immunol. 28:573–621. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Riley SA, Mani V, Goodman MJ, Dutt S and
Herd ME: Microscopic activity in ulcerative colitis: What does it
mean? Gut. 32:174–178. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barton JR, Gillon S and Ferguson A:
Incidence of inflammatory bowel disease in Scottish children
between 1968 and 1983; marginal fall in ulcerative colitis,
three-fold rise in Crohn's disease. Gut. 30:618–622. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Armitage E, Drummond H, Ghosh S and
Ferguson A: Incidence of juvenile-onset Crohn's disease in
Scotland. Lancet. 353:1496–1497. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Greenberg GR, Feagan BG, Martin F,
Sutherland LR, Thomson AB, Williams CN, Nilsson LG and Persson T:
Canadian Inflammatory Bowel Disease Study Group: Oral budesonide as
maintenance treatment for Crohn's disease: A placebo-controlled,
dose-ranging study. Gastroenterology. 110:45–51. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rutgeerts PJ: Prevention of early
recurrence of Crohn's disease after ileal resection with ileocolic
anastomosis. Eur J Gastroenterol Hepatol. 6:113–116. 1994.
View Article : Google Scholar
|
|
21
|
Halme L, Paavola-Sakki P, Turunen U,
Lappalainen M, Farkkila M and Kontula K: Family and twin studies in
inflammatory bowel disease. World J Gastroenterol. 12:3668–3672.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsironi E, Feakins RM, Probert CS, Rampton
DS and Phil D: Incidence of inflammatory bowel disease is rising
and abdominal tuberculosis is falling in Bangladeshis in East
London, United Kingdom. Am J Gastroenterol. 99:1749–1755. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thia KT, Loftus EV Jr, Sandborn WJ and
Yang SK: An update on the epidemiology of inflammatory bowel
disease in Asia. Am J Gastroenterol. 103:3167–3182. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sadlack B, Merz H, Schorle H, Schimpl A,
Feller AC and Horak I: Ulcerative colitis-like disease in mice with
a disrupted interleukin-2 gene. Cell. 75:253–261. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kühn R, Löhler J, Rennick D, Rajewsky K
and Muller W: Interleukin-10-deficient mice develop chronic
enterocolitis. Cell. 75:263–274. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mombaerts P, Mizoguchi E, Grusby MJ,
Glimcher LH, Bhan AK and Tonegawa S: Spontaneous development of
inflammatory bowel disease in T cell receptor mutant mice. Cell.
75:274–282. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gregersen PK and Olsson LM: Recent
advances in the genetics of autoimmune disease. Annu Rev Immunol.
27:363–391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peterson DA, Frank DN, Pace NR and Gordon
JI: Metagenomic approaches for defining the pathogenesis of
inflammatory bowel diseases. Cell Host Microbe. 3:417–427. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ristvedt SL, McFarland EG, Weinstock LB
and Thyssen EP: Patient preferences for CT colonography,
conventional colonoscopy, and bowel preparation. Am J
Gastroenterol. 98:578–585. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Røseth AG, Aadland E, Jahnsen J and
Raknerud N: Assessment of disease activity in ulcerative colitis by
faecal calprotectin, a novel granulocyte marker protein. Digestion.
58:176–180. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tibble J, Teahon K, Thjodleifsson B,
Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol
M and Bjarnason I: A simple method for assessing intestinal
inflammation in Crohn's disease. Gut. 47:506–513. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Costa F, Mumolo MG, Bellini M, Romano MR,
Ceccarelli L, Arpe P, Sterpi C, Marchi S and Maltinti G: Role of
faecal calprotectin as non-invasive marker of intestinal
inflammation. Dig Liver Dis. 35:642–647. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
van Rheenen PF, Van de Vijver E and Fidler
V: Faecal calprotectin for screening of patients with suspected
inflammatory bowel disease: Diagnostic meta-analysis. BMJ.
341:c33692010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
von Roon AC, Karamountzos L, Purkayastha
S, Reese GE, Darzi AW, Teare JP, Paraskeva P and Tekkis PP:
Diagnostic precision of fecal calprotectin for inflammatory bowel
disease and colorectal malignancy. Am J Gastroenterol. 102:803–813.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Limburg PJ, Ahlquist DA, Sandborn WJ,
Mahoney DW, Devens ME, Harrington JJ and Zinsmeister AR: Fecal
calprotectin levels predict colorectal inflammation among patients
with chronic diarrhea referred for colonoscopy. Am J Gastroenterol.
95:2831–2837. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Costa F, Mumolo MG, Ceccarelli L, Bellini
M, Romano MR, Sterpi C, Ricchiuti A, Marchi S and Bottai M:
Calprotectin is a stronger predictive marker of relapse in
ulcerative colitis than in Crohn's disease. Gut. 54:364–368. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Røseth AG, Aadland E and Grzyb K:
Normalization of faecal calprotectin: A predictor of mucosal
healing in patients with inflammatory bowel disease. Scand J
Gastroenterol. 39:1017–1020. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bunn SK, Bisset WM, Main MJ, Gray ES,
Olson S and Golden BE: Fecal calprotectin: Validation as a
noninvasive measure of bowel inflammation in childhood inflammatory
bowel disease. J Pediatr Gastroenterol Nutr. 33:14–22. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fireman Z, Mahajna E, Broide E, Shapiro M,
Fich L, Sternberg A, Kopelman Y and Scapa E: Diagnosing small bowel
Crohn's disease with wireless capsule endoscopy. Gut. 52:390–392.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Crama-Bohbouth G, Pena AS, Biemond I,
Verspaget HW, Blok D, Arndt JW, Weterman IT, Pauwels EK and Lamers
CB: Are activity indices helpful in assessing active intestinal
inflammation in Crohn's disease? Gut. 30:1236–1240. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Modigliani R, Mary JY, Simon JF, Cortot A,
Soule JC, Gendre JP and Rene E: Clinical, biological, and
endoscopic picture of attacks of Crohn's disease. Evolution on
prednisolone. Groupe d'Etude Thérapeutique des Affections
Inflammatoires Digestives. Gastroenterology. 98:811–818. 1990.
|
|
42
|
Cellier C, Sahmoud T, Froguel E, Adenis A,
Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY and
Modigliani R: Correlations between clinical activity, endoscopic
severity, and biological parameters in colonic or ileocolonic
Crohn's disease. A prospective multicentre study of 121 cases. The
Groupe d'Etudes Thérapeutiques des Affections Inflammatoires
Digestives. Gut. 35:231–235. 1994.
|
|
43
|
Biancone L, De Nigris F, Del Vecchio
Blanco G, Monteleone I, Vavassori P, Geremia A and Pallone F:
Review article: Monitoring the activity of Crohn's disease. Aliment
Pharmacol Ther. 16 Suppl 4:29–33. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tibble JA, Sigthorsson G, Bridger S,
Fagerhol MK and Bjarnason I: Surrogate markers of intestinal
inflammation are predictive of relapse in patients with
inflammatory bowel disease. Gastroenterology. 119:15–22. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Modigliani R: Endoscopic management of
inflammatory bowel disease. Am J Gastroenterol. 89:S53–S65.
1994.PubMed/NCBI
|
